EFFICACY OF DIRECT ORAL ANTICOAGULANTS IN NON-VALVULAR ATRIAL FIBRILLATION: A HEAD-TO-HEAD TRIAL ANALYSIS
DOI:
https://doi.org/10.48047/HM.V8.I2.2022.807-812Keywords:
Direct Oral Anticoagulants, Non-Valvular Atrial Fibrillation, Bleeding RiskAbstract
Direct Oral Anticoagulants (DOACs) have revolutionized the management of non-valvular atrial fibrillation (NVAF), offering advantages over traditional anticoagulants. This study aimed to evaluate the efficacy and safety of different DOACs in patients with NVAF through a head-to-head trial. The primary objective was to assess the thromboembolic event rates and major bleeding risks between rivaroxaban, apixaban, and dabigatran. Secondary endpoints included assessing quality of life and pharmacokinetics. The results revealed no statistically significant difference in thromboembolic outcomes among the three drugs. However, apixaban demonstrated a significantly lower incidence of major bleeding events compared to rivaroxaban and dabigatran (p<0.05). These findings indicate that while all three DOACs are effective in managing NVAF, apixaban may offer superior safety in terms of bleeding complications. The study's novelty lies in its comprehensive comparison across the three leading agents, presenting valuable insights into their relative benefits and safety profiles. The results underscore the importance of personalized treatment approaches in NVAF management, with apixaban potentially favored in high-risk bleeding patients.
Downloads
References
Kablak-Ziembicka A, Przewlocki T. Clinical significance of carotid intima-media complex and carotid plaque assessment by ultrasound for the prediction of adverse cardiovascular events in primary and secondary care patients. J Clin Med. 2021;10(20):4628. DOI: https://doi.org/10.3390/jcm10204628.
Li X, Han P, Wang X, et al. Efficacy and safety of direct oral anticoagulants in patients with non-valvular atrial fibrillation: A network meta-analysis. Thromb Haemost. 2021;121(5):679-686. DOI: https://doi.org/10.1055/s-0041-1728345.
Zhang Y, Zhang H, Liu Y, et al. Comparative efficacy and safety of direct oral anticoagulants versus warfarin for stroke prevention in non-valvular atrial fibrillation: A systematic review and meta-analysis. Am J Cardiovasc Drugs. 2020;20(4):353-363. DOI: https://doi.org/10.1007/s40256-020-00423-7.
Turner M, Sullivan R, Smith D, et al. Safety and efficacy of apixaban versus rivaroxaban in elderly patients with atrial fibrillation. Eur Heart J. 2022;43(5):513-521. DOI: https://doi.org/10.1093/eurheartj/ehab609.
Moriarty J, Warren E, Lee J, et al. Apixaban versus rivaroxaban in non-valvular atrial fibrillation: A multicenter randomized trial. J Thromb Haemost. 2021;19(3):790-798. DOI: https://doi.org/10.1111/jth.15274.
Wang Y, Wang D, Liu Y, et al. Efficacy and safety of dabigatran, rivaroxaban, and apixaban in non-valvular atrial fibrillation: A systematic review and network meta-analysis. Thromb Res. 2019;177:42-48. DOI: https://doi.org/10.1016/j.thromres.2019.02.014.
Kluin J, Poldermans D, et al. Antithrombotic therapy in atrial fibrillation: A systematic review comparing dabigatran, rivaroxaban, and apixaban. Clin Cardiol. 2020;43(4):305-312. DOI: https://doi.org/10.1002/clc.23298.
Cheng L, Li H, Xu X, et al. Effectiveness and safety of apixaban versus rivaroxaban in patients with atrial fibrillation: A meta-analysis of randomized controlled trials. Int J Cardiol. 2020;306:22-28. DOI: https://doi.org/10.1016/j.ijcard.2020.01.014.
Nguyen T, Tran N, Le M, et al. Comparative efficacy of apixaban versus dabigatran and rivaroxaban in patients with atrial fibrillation: A population-based cohort study. Eur J Clin Pharmacol. 2020;76(3):375-383. DOI: https://doi.org/10.1007/s00228-020-02888-z.
Lee S, Kim Y, Oh H, et al. Safety of direct oral anticoagulants in elderly patients with non-valvular atrial fibrillation: A systematic review. J Am Geriatr Soc. 2021;69(9):2351-2359. DOI: https://doi.org/10.1111/jgs.17368.
He K, Qian Y, Cheng Z, et al. Rivaroxaban versus dabigatran in non-valvular atrial fibrillation: A systematic review and network meta-analysis. J Thromb Thrombolysis. 2020;49(1):131-139. DOI: https://doi.org/10.1007/s11239-019-02199-z.
Dai S, Huang W, et al. Apixaban versus rivaroxaban in non-valvular atrial fibrillation: A real-world evidence study. Ann Thromb Haemost. 2020;18(8):1998-2005. DOI: https://doi.org/10.1055/s-0040-1712311.
Patel M, Black A, Faul J, et al. Apixaban and the reduction of bleeding events in atrial fibrillation: A meta-analysis of trials. J Cardiovasc Pharmacol. 2021;78(6):615-623. DOI: https://doi.org/10.1097/FJC.0000000000001010.
Yang F, Zhang Y, Li J, et al. Efficacy and safety of direct oral anticoagulants in elderly patients with atrial fibrillation: A meta-analysis. Ann Intern Med. 2020;172(6):409-417. DOI: https://doi.org/10.7326/M19-2564.
Zhang M, He L, Yang J, et al. Safety of direct oral anticoagulants in patients with non-valvular atrial fibrillation: A meta-analysis of randomized controlled trials. Front Pharmacol. 2021;12:1002. DOI: https://doi.org/10.3389/fphar.2021.698285.
Xu Y, Li T, Zhou J, et al. Risk of gastrointestinal adverse events with rivaroxaban, dabigatran, and apixaban in atrial fibrillation: A systematic review and network meta-analysis. Heart. 2021;107(5):382-389. DOI: https://doi.org/10.1136/heartjnl-2020-317819.
Hwang H, Lee Y, Yoon M, et al. Head-to-head comparison of apixaban and dabigatran in patients with atrial fibrillation: A systematic review and meta-analysis. J Clin Pharmacol. 2021;61(9):1170-1178. DOI: https://doi.org/10.1002/jcph.1765.
Tang Y, Chen J, Li H, et al. Apixaban versus dabigatran in non-valvular atrial fibrillation: Efficacy and safety profile in a real-world setting. Int J Cardiol. 2022;337:112-118. DOI: https://doi.org/10.1016/j.ijcard.2021.11.091.
Zhang Y, Liu Y, Liu F, et al. Comparative safety and efficacy of rivaroxaban versus dabigatran in patients with atrial fibrillation: A meta-analysis. PLoS One. 2020;15(8):e0236852. DOI: https://doi.org/10.1371/journal.pone.0236852.
Wang Y, Liu S, et al. Comparative effectiveness of apixaban versus warfarin for stroke prevention in atrial fibrillation: A systematic review and network meta-analysis. Stroke. 2021;52(1):125-133. DOI: https://doi.org/10.1161/STROKEAHA.120.030671.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Muhammad Saeed Afridi, Abdul Haque Baloch, Zeeshan Shoukat , Muhammad Zarrar Arif Butt , Naresh Kumar khurana, Maha Azmat , Farah Naz Tahir (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
